StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) shareholders

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.40+0.06 (+0.42%)

Close on Nov 17, 2026Market cap $979.40MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
73M of 64M shares
Institutional holders
154
52 new, 16 sold out
Net institutional buying
25M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Peter Evan Harwin
Joint filing with Fairmount Funds Management LLC (19.99%), Tomas Kiselak (19.99%) and 1 more
14,069,49419.99%13D (active) amendmentJun 5, 2026
Tomas Kiselak
Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 2 more
7,249,35619.99%13D (active)Apr 28, 2025
JANUS HENDERSON GROUP Ltd.6,273,26210.60%13G (passive) amendmentJun 30, 2026
VHCP Co-Investment Holdings III, LLC
Joint filing with Venrock Healthcare Capital Partners III, L.P. (8.30%), Venrock Healthcare Capital Partners EG, L.P. (8.30%) and 4 more
5,145,3308.30%13G (passive) amendmentJun 30, 2026
FMR LLC
Joint filing with Abigail P. Johnson (14.70%)
4,735,95114.70%13G (passive)May 30, 2025
Franklin Templeton, Inc.3,807,2366.00%13G (passive)Sep 30, 2026
BlackRock, Inc.3,323,3015.20%13G (passive)Sep 30, 2026
VHCP Management EG, LLC
Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more
3,220,3699.90%13G (passive)Apr 28, 2025
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (7.00%), Rajeev Shah (7.00%) and 1 more
3,214,9697.00%13G (passive)Oct 8, 2025
Paradigm BioCapital Advisors LP
Joint filing with Paradigm BioCapital Advisors GP LLC (5.10%), Senai Asefaw, M.D. (5.10%)
3,106,7935.10%13G (passive)Jul 10, 2026
Janus Henderson Group PLC3,105,6696.30%13G (passive) amendmentMar 31, 2026
Bellevue Asset Management AG
Joint filing with Bellevue Group AG (5.00%)
3,057,9965.00%13G (passive) amendmentJun 30, 2026
Deep Track Capital, LP
Joint filing with Deep Track Biotechnology Master Fund, Ltd. (8.64%), David Kroin (8.64%)
2,784,6488.64%13G (passive)Apr 28, 2025
David Kroin
Joint filing with Deep Track Capital, LP (6.99%), Deep Track Biotechnology Master Fund, Ltd. (6.99%)
2,279,8926.99%13G (passive) amendmentSep 30, 2025
Patrick J. Heron
Joint filing with James N. Topper (5.50%), Albert Cha (5.40%) and 1 more
1,772,1165.50%13G (passive)Apr 28, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of JBIOValueChange% of portfolio
FMR LLC9,126,87714.35%$202.80M+2,041,4540.01%
Jupiter Topco LLC6,273,2629.86%$139.37MNew0.06%
Fairmount Funds Management LLC4,553,4947.16%$101.18M–6.69%
Ra Capital Management, L.P.3,671,0835.77%$81.57M–0.71%
VR Adviser, LLC3,220,3645.06%$71.56M–2.17%
Bellevue Group AG3,057,9964.81%$67.95M−443,5061.43%
Paradigm Biocapital Advisors LP2,857,4054.49%$63.49MNew1.19%
BlackRock, Inc.2,801,4514.40%$62.25M+487,5020.00%
Franklin Resources Inc2,792,0804.39%$62.04MNew0.01%
State Street Corp2,335,2853.67%$51.89M+1,679,5950.00%
Vanguard Capital Management LLC2,244,7733.53%$49.88M+448,1210.00%
Adage Capital Partners Gp, L.L.C.1,910,8123.00%$42.46MNew0.06%
Polar Capital Holdings Plc1,846,9822.90%$41.04MNew0.10%
Avidity Partners Management LP1,700,7082.67%$37.79M−1,100,7086.05%
Remedium Capital Partners, LLC1,577,7502.48%$35.06M–7.76%
Soleus Capital Management, L.P.1,550,6902.44%$34.46M+753,9461.19%
JPMorgan Chase & Co1,475,0792.32%$32.61M+1,459,2160.00%
Baker Bros. Advisors LP1,230,4261.93%$27.34M−410,7110.14%
Logos Global Management LP1,125,0001.77%$25.00M+725,0001.08%
Versant Venture Management, LLC991,7831.56%$22.04M−534,03713.55%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202615473M100.0%52 / 6026 / 1631M7M
Q1 202612051M80.8%29 / 3933 / 1310M4M
Q4 202510547M74.0%33 / 4315 / 620M5M
Q3 20257832M49.7%8 / 2322 / 31M1M
Q2 20257332M49.6%73 / 00 / 032M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

126 funds held JBIO in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of JBIOValue% of fundAs of
Vanguard Total Stock Market Index Fund1,699,3432.67%$37.76M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,533,5732.41%$34.08M0.32%Jun 30, 2026
Franklin Small Cap Value Fund1,412,5592.22%$27.90M0.65%Jul 31, 2026
Fidelity Growth Company Fund1,009,9571.59%$21.25M0.02%May 31, 2026
Fidelity Stock Selector Small Cap Fund908,1461.43%$17.94M0.24%Jul 31, 2026
iShares Russell 2000 ETF852,0701.34%$18.93M0.02%Jun 30, 2026
Fidelity Small Cap Growth Fund779,9151.23%$15.40M0.18%Jul 31, 2026
Janus Henderson Global Life Sciences Fund716,7991.13%$15.93M0.27%Jun 30, 2026
Fidelity Advisor Biotechnology Fund698,6711.10%$13.80M0.63%Jul 31, 2026
JPMorgan Small Cap Growth Fund677,7661.07%$15.06M0.58%Jun 30, 2026
Select Health Care Portfolio640,0001.01%$13.47M0.23%May 31, 2026
Fidelity Series Small Cap Opportunities Fund589,2000.93%$11.64M0.25%Jul 31, 2026
Vanguard Extended Market Index Fund484,9640.76%$10.78M0.01%Jun 30, 2026
Franklin Biotechnology Discovery Fund479,9490.75%$9.48M0.82%Jul 31, 2026
Franklin Small Cap Growth Fund432,7090.68%$8.55M0.35%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Tom FrohlichChief Executive Officer, Director86,3310.14%Feb 13, 2026
Elizabeth BaltaSee Remarks28,1250.04%Feb 13, 2026
Bradford D. DahmsChief Financial Officer37,8130.06%Feb 13, 2026
Andrew James KingSee Remarks386,1130.61%Feb 13, 2026
Hetal KocinskyChief Medical Officer––May 1, 2025
Jonathan QuickSee Remarks––May 1, 2025
Mark EisnerDirector––Jun 26, 2026
Eric DobmeierDirector––Jun 11, 2026
Erin LavelleDirector––Jun 11, 2026
Healthcare Co-Invest IV L.P. FairmountDirector, 10% owner––Jun 11, 2026
Healthcare Fund II L.P. FairmountDirector, 10% owner4,553,4947.16%Jun 11, 2026
Tomas KiselakDirector, 10% owner––Jun 11, 2026
Funds Management LLC FairmountDirector, 10% owner––Jun 11, 2026
Peter Evan HarwinDirector, 10% owner––Jun 11, 2026
Lawrence Otto KleinDirector86,2150.14%Jun 11, 2026
Christopher W. CainDirector––Jun 11, 2026
Ra Capital Management, L.P.10% owner––Apr 30, 2025
Peter Kolchinsky10% owner1,287,8582.03%Apr 30, 2025
Rajeev M. Shah10% owner7,893,67812.41%Apr 30, 2025
Capital Healthcare Fund LP RA10% owner––Apr 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Bradford D. Dahms
Chief Financial Officer
Feb 12, 2026Award+37,813––37,813
Tom Frohlich
Chief Executive Officer, Director
Feb 12, 2026Award+78,750––86,331
Andrew James King
See Remarks
Feb 12, 2026Award+41,250––386,113
Elizabeth Balta
See Remarks
Feb 12, 2026Award+28,125––28,125
Healthcare Fund II L.P. Fairmount
Director, 10% owner
Oct 6, 2025Award+1,333,126$9.14$12.18M1,897,677
Tom Frohlich
Chief Executive Officer, Director
May 16, 2025Buy+6,000$7.40$44.40K6,000
Peter Kolchinsky
10% owner
Apr 28, 2025Other+1,062,326––1,287,858
Benjamin T. Dake
SEE REMARKS
Aug 1, 2024Option exercise+1,507$1.74$2.62K14,252
Benjamin T. Dake
SEE REMARKS
Jul 31, 2024Option exercise+11,454$1.74$19.93K12,745
Rajeev M. Shah
Director, 10% owner
Jun 17, 2024Buy+928,110$1.67$1.55M7,893,678
George A. Eldridge
SEE REMARKS
Jun 14, 2024Option exercise+15,000$2.14$32.10K20,022
George A. Eldridge
SEE REMARKS
Jun 14, 2024Sale(10b5-1 plan)−15,000$25.03$375.45K5,022
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Jun 14, 2024Option exercise+10,600$14.59$154.65K10,600
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Jun 14, 2024Sale(10b5-1 plan)−10,600$25.00$265.00K0
Hunter Gillies
CHIEF MEDICAL OFFICER
Jun 13, 2024Option exercise+6,000$2.14$12.84K11,602
Hunter Gillies
CHIEF MEDICAL OFFICER
Jun 13, 2024Sale(10b5-1 plan)−6,000$24.50$147.00K5,602
Hunter Gillies
CHIEF MEDICAL OFFICER
May 17, 2024Option exercise+4,000$2.14$8.56K9,602
Hunter Gillies
CHIEF MEDICAL OFFICER
May 17, 2024Sale(10b5-1 plan)−3,914$21.07$82.47K5,688
Hunter Gillies
CHIEF MEDICAL OFFICER
May 17, 2024Sale(10b5-1 plan)−86$21.86$1.88K5,602
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 16, 2024Sale(10b5-1 plan)−8,707$21.52$187.37K1,293
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 16, 2024Sale(10b5-1 plan)−1,293$21.92$28.34K0
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 16, 2024Option exercise+10,000$2.14$21.40K10,000
Marinus Verwijs
CHIEF TECHNICAL OFFICER
May 2, 2024Sale−1,981$21.02$41.64K0
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 1, 2024Sale(10b5-1 plan)−1,357$19.91$27.02K0
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 1, 2024Sale(10b5-1 plan)−965$20.87$20.14K0
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 1, 2024Sale(10b5-1 plan)−9,035$20.34$183.77K965
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
May 1, 2024Option exercise+10,000$2.14$21.40K10,000
Hunter Gillies
CHIEF MEDICAL OFFICER
Apr 17, 2024Sale(10b5-1 plan)−3,689$22.30$82.26K3,562
Hunter Gillies
CHIEF MEDICAL OFFICER
Apr 17, 2024Option exercise+4,000$1.74$6.96K7,251
Hunter Gillies
CHIEF MEDICAL OFFICER
Apr 17, 2024Sale(10b5-1 plan)−311$23.33$7.26K3,251
Benjamin T. Dake
SEE REMARKS
Apr 17, 2024Option exercise+6,853$2.14$14.67K8,144
Benjamin T. Dake
SEE REMARKS
Apr 17, 2024Sale(10b5-1 plan)−338$23.17$7.83K1,359
Benjamin T. Dake
SEE REMARKS
Apr 17, 2024Sale(10b5-1 plan)−68$23.97$1.63K1,291
Benjamin T. Dake
SEE REMARKS
Apr 17, 2024Sale(10b5-1 plan)−6,447$22.32$143.90K1,697
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 16, 2024Option exercise+10,000$2.14$21.40K10,000
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 16, 2024Sale(10b5-1 plan)−4,491$24.40$109.58K5,509
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 16, 2024Sale(10b5-1 plan)−5,509$24.94$137.39K0
George A. Eldridge
SEE REMARKS
Apr 10, 2024Option exercise+7,500$2.14$16.05K9,460
George A. Eldridge
SEE REMARKS
Apr 10, 2024Sale(10b5-1 plan)−6,729$26.77$180.14K2,731
George A. Eldridge
SEE REMARKS
Apr 10, 2024Sale(10b5-1 plan)−771$27.56$21.25K1,960
David S. Grayzel
Director
Apr 9, 2024Sale−11,882$28.15$334.48K14,502
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Apr 1, 2024Option exercise+5,300$14.59$77.33K5,300
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Apr 1, 2024Sale(10b5-1 plan)−1,504$30.00$45.12K0
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Apr 1, 2024Sale(10b5-1 plan)−3,796$28.87$109.59K1,504
Benjamin T. Dake
SEE REMARKS
Apr 1, 2024Option exercise+3,325$10.61$35.28K4,616
Benjamin T. Dake
SEE REMARKS
Apr 1, 2024Sale(10b5-1 plan)−3,325$31.97$106.30K1,291
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 1, 2024Sale(10b5-1 plan)−1,647$29.90$49.25K3,851
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 1, 2024Sale(10b5-1 plan)−4,502$28.96$130.38K5,498
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 1, 2024Option exercise+10,000$2.14$21.40K10,000
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 1, 2024Sale(10b5-1 plan)−1,000$31.95$31.95K0
Timothy P. Noyes
CHIEF EXECUTIVE OFFICER, Director
Apr 1, 2024Sale(10b5-1 plan)−2,851$31.02$88.44K1,000
George A. Eldridge
SEE REMARKS
Apr 1, 2024Sale(10b5-1 plan)−12,495$31.23$390.22K1,960
George A. Eldridge
SEE REMARKS
Apr 1, 2024Option exercise+12,495$2.14$26.74K14,455
Hunter Gillies
CHIEF MEDICAL OFFICER
Mar 28, 2024Option exercise+9,000$2.14$19.26K12,251
Hunter Gillies
CHIEF MEDICAL OFFICER
Mar 28, 2024Sale(10b5-1 plan)−9,000$29.50$265.50K3,251
Benjamin T. Dake
SEE REMARKS
Mar 27, 2024Sale(10b5-1 plan)−11,068$27.97$309.57K1,291
Benjamin T. Dake
SEE REMARKS
Mar 27, 2024Option exercise+11,068$10.61$117.43K12,359
Benjamin T. Dake
SEE REMARKS
Mar 25, 2024Sale(10b5-1 plan)−3,432$28.01$96.13K1,291
Benjamin T. Dake
SEE REMARKS
Mar 25, 2024Option exercise+3,432$10.61$36.41K4,723
Marinus Verwijs
CHIEF TECHNICAL OFFICER
Mar 19, 2024Sale(10b5-1 plan)−2,764$26.46$73.14K0

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
21.28%
10M shares short
Days to cover
14.1
At 1M shares a day
Change since last report
-7.5%
From 11M shares
Short volume, 20 days
51.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jade Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,535 shares on Sep 18, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Atlas Venture Associates XII, L.P.
Shareholder
Jun 25, 2025235$2.46KJun 25, 2025Private Placement
Atlas Venture Fund XII, L.P.
Shareholder
Jun 25, 202528,977$303.68KJun 25, 2025Private Placement
Atlas Venture Fund XII, L.P.
Shareholder
Jun 24, 202516,132$159.22KJun 24, 2025Private Placement
Atlas Venture Associates XII, L.P.
Shareholder
Jun 24, 2025131$1.29KJun 24, 2025Private Placement
Atlas Venture Fund XII, L.P.
Shareholder
May 6, 20255,883$67.65KMay 6, 2025Private Placement
Atlas Venture Associates XII, L.P.
Shareholder
May 6, 202548$552May 6, 2025Private Placement
Marinus Verwijs
Officer
Jun 14, 202410,600$265.00KJun 14, 2024Stock Option Exercise
Hunter Gillies
Officer
Jun 13, 20246,000$147.00KJun 13, 2024Stock Option Exercise
Hunter Gillies
Officer
May 17, 20244,000$84.33KMay 17, 2024Stock Option Exercise
Timothy P. Noyes
Officer, Director
May 16, 202410,000$215.76KMay 16, 2024Stock Option Exercise
Marinus Verwijs
Officer
May 2, 20241,981$41.63KMay 2, 2024ESPP
Timothy P. Noyes
Officer, Director
May 1, 202411,357$230.94KMay 1, 2024Employee Stock Purchase Plan
Benjamin T. Dake
Officer
Apr 17, 20246,853$161.87KApr 17, 2024Options Grant
Hunter Gillies
Officer
Apr 17, 20244,000$89.52KApr 17, 2024Stock Option Exercise
Timothy P. Noyes
Officer, Director
Apr 16, 202410,000$246.97KApr 16, 2024Stock Option Exercise

See a number that looks wrong?